Evidence map›Paper›PMID 34142073›Full record

ArticleJHEP reports : innovation in hepatology2021

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

Thierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, Valentina Peta, Sepideh Akhavan, Victor de Ledinghen, Fabien Zoulim, Didier Samuel, Philippe Mathurin, Vlad Ratziu and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01953458 (Therapeutic Option for Hepatitis B and C), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01953458 unknown statusnot on this map

Therapeutic Option for Hepatitis B and C: a French Cohort

TypeobservationalSponsorANRS, Emerging Infectious DiseasesRan2012 to 2024Enrolled20,902ConditionsViral Hepatitis B, Viral Hepatitis C
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Thierry PoynardAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.
Jean Marc LacombeSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Olivier DeckmynBioPredictive, Paris, France.
Valentina PetaSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
Sepideh AkhavanAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.
Victor de LedinghenHepatology Unit Hôpital Haut-Lévêque, Pessac, and INSERM U1053, Université Bordeaux Segalen, Bordeaux, France.
Fabien ZoulimHospices civils de Lyon, Hôpital Croix Rousse, Department of Hepatology, INSERM U1052, Université de Lyon, Lyon, France.
Didier SamuelAP-HP, Hospital Paul Brousse, Hepatology Department, UMR-S1193, Villejuif, France.
Philippe MathurinCHRU Claude Huriez, Hepatology Department Lille, France.
Vlad RatziuAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.
Dominique ThabutAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.
Chantal HoussetSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
Hélène FontaineAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, AP-HP, Hôpital Cochin, Hepatology Department, Paris, France.
Stanislas PolAssistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Gastroenterology, AP-HP, Hôpital Cochin, Hepatology Department, Paris, France.
Fabrice CarratSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
Sorbonne Université · FRBiopredic (France) · FRHôpital Cochin · FRInserm · FRCentre de Recherche en Cancérologie de Lyon · FRCentre Hospitalier Universitaire de Lille · FRHôpital Paul-Brousse · FRInstitut Pierre Louis d‘Épidémiologie et de Santé Publique · FRPitié-Salpêtrière Hospital · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThe Liver Cancer Risk test algorithm (LCR1-LCR2) is a multianalyte blood test combining proteins involved in liver cell repair (apolipoprotein-A1 and haptoglobin), known hepatocellular carcinoma (HCC) risk factors (sex, age, and gamma-glutamyl transferase), a marker of fibrosis (alpha2-macroglobulin) and alpha-fetoprotein (AFP), a specific marker of HCC. The aim was to externally validate the LCR1-LCR2 in patients with chronic HCV (CHC) treated or not with antivirals.

methodsPre-included patients were from the Hepather cohort, a multicentre prospective study in adult patients with CHC in France. LCR1-LCR2 was assessed retrospectively in patients with the test components and AFP, available at baseline. The co-primary study outcome was the negative predictive value (NPV) of LCR1-LCR2 for the occurrence of HCC at 5 years and for survival without HCC according to the predetermined LCR1-LCR2 cut-offs. The cut-offs were adjusted for risk covariables and for the response to HCV treatment, and were quantified using time-dependent proportional hazards models.

resultsIn total, 4,903 patients, 1,026 (21.9%) with baseline cirrhosis, were included in the study. Patients were followed for a median of 5.7 (IQR 4.2-11.3) years. A total of 3,788/4,903 (77.3%) patients had a sustained virological response. There were 137 cases of HCC at 5 years and 214 at the end of follow-up. HCC occurred at 5 years in 24/3,755 patients with low-risk LCR1-LCR2 compared with 113/1,148 patients with high-risk LCR1-LCR2. The NPV was 99.4% (95% CI 99.1-99.6). Similar findings (hazard ratio, 10.8; 95% CI, 8.1-14.3;

conclusionsThe results showed that LCR1-LCR2 can be used to successfully identify patients with HCV at very low risk of HCC at 5 years. LAY SUMMARY: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide and the fastest growing cause of cancer death in many countries. We constructed and internally validated a new multianalyte blood test to assess this Liver Cancer Risk (LCR1-LCR2). This study confirmed the performance of LCR1-LCR2 in patients with chronic HCV in the national French cohort Hepather, and its ability to identify patients at a very low risk of HCC at 5 years. CLINICAL TRIALS REGISTRATION: The study is registered at ClinicalTrials.gov (NCT01953458).

Indexed as

AFPAFP, alpha-fetoproteinAUROC, area under the receiver operating curveCHC, chronic HCVCirrhosisDAA, direct-acting antiviralsEASL, European Association for the Study of the LiverFIB4, Fibrosis-4Fibrosis progressionFibroTest™HCC, hepatocellular carcinomaLCR1-LCR2LCR, Liver Cancer RiskLiver Cancer RiskMulti-analyte blood testNNS, needed to screenNPV, negative predictive valueSIR, standardised incidence ratioSTARD, Standards for the Reporting of Diagnostic Accuracy StudiesSTROBE, Strengthening the Reporting of Observational Studies in EpidemiologySurveillanceSVR, sustained virological responseVCTE, vibration-controlled transient elastography

Identifiers

PMID34142073
PMCPMC8187244
OpenAlexW3157465318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.